<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660372</url>
  </required_header>
  <id_info>
    <org_study_id>CO-150121160547-DHCT</org_study_id>
    <nct_id>NCT02660372</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Simeticone Brands in Adults With Functional Dyspepsia</brief_title>
  <official_title>A Multi-center, Randomized, Observer-blind, Parallel Group, 8-weeks Non-inferiority Clinical Trial to Compare the Efficacy and Safety of Two Brands of Simeticone for Symptomatic Treatment of Functional Dyspepsia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Consumer and Personal Products Worldwide</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to show non-inferiority of two brands of simeticone in adult&#xD;
      patients suffering from functional dyspepsia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, observer-blind, parallel-group, 8-weeks, non-inferiority&#xD;
      clinical trial to compare the efficacy and safety of two brands of Simeticone for symptomatic&#xD;
      treatment of functional dyspepsia in adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aggregate symptom score calculated from subjects assessment of 10 individual upper gastrointestinal symptoms 8 weeks after start of treatments</measure>
    <time_frame>8 weeks</time_frame>
    <description>Specific questionnaire with a 4 point scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Imonogas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imonogas 120 mg, 1 capsule three times daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Espumisan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Espumisan 40 mg, 2 capsules four times daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imonogas</intervention_name>
    <description>Simethicone 120 mg in gel capsules</description>
    <arm_group_label>Imonogas</arm_group_label>
    <other_name>Imogas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Espumisan</intervention_name>
    <description>Simethicone 40 mg in gel capsules</description>
    <arm_group_label>Espumisan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects of the age of 18 years or older with a suspected diagnosis of functional&#xD;
             dyspepsia according to Rome III criteria (see Appendix A) e.g. subjects suffering from&#xD;
             bothersome postprandial fullness or early satiation or epigastric pain or epigastric&#xD;
             burning AND no evidence of structural disease (including upper GI endoscopy) that is&#xD;
             likely to explain the symptoms. Criteria fulfilled for the last 3 months. Symptom&#xD;
             onset at least 6 months prior to diagnosis.&#xD;
&#xD;
          2. Have a Body Mass Index (BMI) between 18.5-30.&#xD;
&#xD;
          3. Absence of significant structural/organic abnormalities on abdominal ultrasound and&#xD;
             upper gastrointestinal endoscopy performed within the last 3 months prior to baseline&#xD;
             to exclude a structural cause for the symptoms.&#xD;
&#xD;
          4. Negative Helicobacter Pylori urea breath test.&#xD;
&#xD;
          5. Presence of at least three out of the assessed ten symptoms judged to be at least of&#xD;
             moderate or severe intensity, assessed after withdrawal of any medication potentially&#xD;
             affecting the gastrointestinal tract and at least 7 days wash-out period.&#xD;
&#xD;
          6. Females of childbearing potential must have a negative urine pregnancy test at the&#xD;
             baseline visit.&#xD;
&#xD;
          7. Male or non-pregnant, non-lactating female agree to the contraceptive requirements&#xD;
             (including female partner's use of a highly effective form of birth control for at&#xD;
             least 3 months before the study, during the study and for 3 months after the last dose&#xD;
             of study drug) as outlined in Section 10.7.4.&#xD;
&#xD;
          8. Able to read and understand the local language;&#xD;
&#xD;
          9. Provide a signed and dated informed consent form prior to any study-related&#xD;
             procedures;&#xD;
&#xD;
         10. Willing and able to comply with all study procedures and attend the scheduled visits&#xD;
             for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects meeting the diagnostic Rome III criteria for Irritable Bowel Disease (IBS)&#xD;
             (see Appendix A).&#xD;
&#xD;
          2. a) severe gastroesophageal reflux symptoms (typical symptoms - heartburn,&#xD;
             regurgitation, dysphagia, odynophagia, and/or signs of reflux at upper GI endoscopy)&#xD;
             at Screening visit.&#xD;
&#xD;
             b) predominant gastroesophageal reflux symptoms defined as a Subject's Symptom&#xD;
             Severity Score of 2 or more for heartburn and regurgitation at Baseline visit after&#xD;
             the 7-days wash-out period (see questionnaire in Appendix B).&#xD;
&#xD;
          3. Significant medical condition which may interfere with a subject's participation in&#xD;
             the study, e.g. diabetes mellitus, thyroid dysfunction, renal insufficiency,&#xD;
             congestive heart failure, electrolyte disturbances or autoimmune diseases requiring&#xD;
             immunosuppressive treatment.&#xD;
&#xD;
          4. Known hepatic, biliary or pancreatic disease.&#xD;
&#xD;
          5. Known lactose or gluten intolerance or celiac disease.&#xD;
&#xD;
          6. Known HIV positive or AIDS.&#xD;
&#xD;
          7. Suspected alcohol or substance abuse (e.g., amphetamines, benzodiazepines, cocaine,&#xD;
             marijuana, opiates).&#xD;
&#xD;
          8. Unwillingness or inability to withdraw and abstain from medication which is likely to&#xD;
             affect gastrointestinal function or symptoms during the 7-days wash-out period and&#xD;
             throughout the study period, including the following drugs:&#xD;
&#xD;
               -  gastrointestinal medications including antispasmodics, prokinetics, proton pump&#xD;
                  inhibitors, H2 blockers, antacids, alginate, bismuth preparations, sucralfate,&#xD;
                  misoprostol, charcoal, diosmectite, enzymes (e.g. Kreon®, Mezim®).&#xD;
&#xD;
               -  other medications that could interfere with gastrointestinal function e.g.&#xD;
                  antibiotics (except for local application), theophylline, NSAIDs (except for&#xD;
                  low-dose aspirin for prevention of heart disease), opioid analgesics, codeine,&#xD;
                  ulcerogenic substances (e.g. oral glucocorticoids), anxiolytics, neuroleptics,&#xD;
                  antidepressants, and/or others in the judgment of the investigator.&#xD;
&#xD;
          9. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         10. Males with a pregnant partner or a partner who is currently trying to become pregnant.&#xD;
&#xD;
         11. Known sensitivity to the investigational products.&#xD;
&#xD;
         12. Subjects who were previously screened and ineligible or were randomized to receive&#xD;
             investigational product.&#xD;
&#xD;
         13. Currently participating in another clinical trial or has done so in the past 30 days.&#xD;
&#xD;
         14. Subjects who are related to those persons involved directly or indirectly with the&#xD;
             conduct of this study (i.e., principal investigator, subinvestigators, study&#xD;
             coordinators, other site personnel, employees of Johnson &amp; Johnson LLC or McNeil AB&#xD;
             subsidiaries, contractors of Johnson &amp; Johnson LLC or McNeil AB, and the families of&#xD;
             each).&#xD;
&#xD;
         15. Other severe, acute or chronic, medical or psychiatric condition(s) or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the subject&#xD;
             inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Polyclinic #2 of Moscow Health Department</name>
      <address>
        <city>Moscow</city>
        <zip>117556</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

